PFE News 31.00 04/22/2014 18:17:22 Pfizer Inc (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 31.00 $PFE

Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - 41 mins ago
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....

A Doozy of a Pharma Rumor
Brian Orelli, The Motley Fool - Motley Fool - 47 mins ago
The latest health care acquisition rumor is a doozy. According to multiple news outlets, Pfizer was in talks with AstraZeneca to acquire the company for over $100 billion, although the companies apparently broke off talks. Interestingly, this...

Most active New York Stock Exchange-traded stocks
AP - 1 hr 14 mins ago
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:

Final Glance: Pharmaceuticals companies
AP - 1 hr 14 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Billionaire Ken Fisher's Top Stock Picks
Nicole Seghetti, The Motley Fool - Motley Fool - Tue Apr 22, 3:08PM CDT
Money managers must disclose their stock holdings every quarter, giving investors like you and me a peek into their portfolios. Based on his firm's first-quarter 13F SEC filing, here are multibillion-dollar fund manager Ken Fisher's top three stock...

This is the 1 Thing AstraZeneca Should Do to Improve Shareholder Value
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:05PM CDT
It's only Tuesday and this has already been an exciting week in the health-care sector. I'm speaking of the news this weekend that pharma giant Pfizer reportedly considered making a $101 billion bid for U.K.-based rival AstraZeneca , a 27%...

Midday Glance: Pharmaceuticals companies
AP - Tue Apr 22, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Active Equities under the Scanner -- Research on JPMorgan Chase, Pfizer, General Motors, and Nokia
PR Newswire - Tue Apr 22, 12:13PM CDT
The trading session on Monday, April 21, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,449.25, up 0.25% and the NASDAQ Composite closed at 4,121.55, up 0.64%. The S&P 500 finished the session 0.38% higher at 1,871.89. The gains were broad based as eight out of ten sectors finished on a higher note. Investor-Edge looks at some of the equities which attracted the most attention and traded the most shares during the session. These include JPMorgan Chase & Co. (NYSE: JPM), Pfizer Inc. (NYSE: PFE), General Motors Co. (NYSE: GM) and Nokia OYJ (NYSE: NOK). Free technical research on JPM, PFE, GM and NOK can be downloaded upon signing up at:

3 Health Care Stocks Moving The Sector Upward
at The Street - Tue Apr 22, 12:02PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.


Novartis reshapes business with GSK, Lilly deals
By JOHN HEILPRIN - AP - Tue Apr 22, 11:02AM CDT
GENEVA (AP) — Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly & Co. that heralds more restructuring in the fast-changing industry.

Pharma deals give stocks a lift
By The Associated Press - AP - Tue Apr 22, 10:55AM CDT
LONDON (AP) — A flurry of deals in the pharmaceutical sector helped to shore up global stock markets on Tuesday.

Novartis Reshapes Portfolio via GSK, Eli Lilly Deals
at The Street - Tue Apr 22, 10:40AM CDT
The Swiss company announces four multibillion-dollar transactions including the $16 billion purchase of GlaxoSmithKline's oncology business.

Today's Health-Care Stocks to Watch: Allergan, Inc., AstraZeneca, Pfizer, and Valeant Pharmaceutical
George Budwell, The Motley Fool - Motley Fool - Tue Apr 22, 9:34AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Allergan , AstraZeneca plc , Pfizer , and Valeant Pharmaceuticals . Valeant makes a play for Allergan Allergan shares are up double digits this...

Stock Market News for April 22, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 9:06AM CDT
Benchmarks ended in the green zone yesterday as investors were encouraged by better-than-expected corporate earnings results

Global Human Reproductive ((Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) Technologies Market 2013-2019
M2 - Tue Apr 22, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcxdpd/human) has announced the addition of the "Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure. Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs). The global human reproductive technologies market is highly fragmented in nature with many companies currently competing in the market. Well established market players such as Merck & Co., Inc., Ferring International Center S.A., Pfizer, Inc. Merck Serono and Bayer AG dominate this market with their proprietary products and predatory growth strategies. Patent repositories of the established market players are restraining the entry and growth of new players entering the market. The global human reproductive technologies market is categorized into the following segments: Infertility Drugs - Gonal-f (recombinant follitropin alfa) - Follistim AQ (follitropin beta) - AndroGel (testosterone) - Testim (testosterone) - Viagra (sildenafil citrate) - Cialis (tadalafil) - Levitra/Staxyn (vardenafil) Infertility Procedures - In Vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI) - Zygote Intrafallopian Transfer (ZIFT) - Gamete Intrafallopian Transfer (GIFT) - Intrauterine Insemination (IUI) Contraceptive Technologies - Drugs - - Oral Contraceptive Pills - - Contraceptive Injectables - - Topical Contraceptives - Devices - - Male Contraceptive Devices (Male Condoms) - - Female Contraceptive Devices Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Human Reproduction Technologies Market, by Infertility Treatment - Global Human Reproductive Technologies Market, by Contraceptive Technologies - Global Human Reproductive Technologies Market Revenue, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/bcxdpd/human

Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:45AM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis
Business Wire - Tue Apr 22, 7:01AM CDT
Pfizer Inc. (NYSE FE) announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 studies showed that tofacitinib, as a 5 mg or a 10 mg dose taken as a pill twice-daily, met the primary efficacy endpoints of statistically significant superiority over placebo at Week 16 in the proportion of subjects achieving a Physician's Global Assessment response of "clear" or "almost clear," and the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index, two commonly used measures of efficacy in psoriasis.

European Stocks Rise, Led by Pharma Sector News
at The Street - Tue Apr 22, 5:17AM CDT
The main European markets open in a buoyant mood after the Easter break.

Global Brain Tumor Therapeutics Pipeline Review 2014 - Analysis of 9 Companies & 19 Drug Profiles
M2 - Tue Apr 22, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9tl8j/brain_tumor) has announced the addition of the "Brain Tumor - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Tumor and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Tumor pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Pfizer Inc. - Bayer AG - Hutchison MediPharma Limited - Advantagene, Inc. - Oncovir, Inc. - DEKK-TEC, Inc. - CalAsia Pharmaceuticals, Inc. - Tolero Pharmaceuticals, Inc. - Dong-A Socio Holdings Co Ltd Drug Profiles - Antibody to Inhibit PGRN for Brain Tumor - Bay-846 - Bi-specific Antibody For Brain Tumor Therapy - Bispecific T-Cell Engager - CIGB-128 - DA-3607 - DC/AAT DC/AAT-Flu DC/KLH - Dendritic Cell Vaccine - GliAtak - HMPL-813 - HOOI - Neural Stem Cells - PF-06463922 - Poly-ICLC - Small Molecule To Inhibit Hsp90 Alpha and TRAP1 For Brain Cancer - TP-0903 - VAL-083 - VO-101 - diaziquone For more information visit http://www.researchandmarkets.com/research/s9...rain_tumor
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 90

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 57

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 63

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Jeff Stern Turns Travel Photography Into a Sensory Memoir

Updated Category News Views 112

Frost in a mountain tent, fermented mare’s milk in a yurt, and coffee in Vietnamese rice paddies are doing more work here than a thousand polished sunset captions ever could. Jeff Stern’s A Change of Scenery, released by Palmetto Publishing on November 17, 2026, comes from a man who spent more than 25 years building brands and then decided the usual labels around...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 118

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 15

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
Saban Center Partnership Gives Health Learning a Lift

Updated Category News Views 82

A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading

Top 5 Most Recently Viewed Articles

Kleo Partners with Londis to Revolutionize Retail Convenience

Updated Category News Views 256

Kleo Teams Up with Londis to Improve Convenience Store Operations Kleo, a leading provider of EPOS systems and self-ordering kiosks, is thrilled to announce a new partnership with Londis, one of the premier convenience store chains in the UK. This collaboration marks an important move toward modernizing Londis's operations and enhancing customer experiences through...

Continue Reading
W&T Offshore Sees Production Growth and Impressive Cash Flow

Updated Category News Views 119

W&T Offshore's Third Quarter Performance Highlights W&T Offshore, Inc. (NYSE: WTI) has reported its operational and financial results for the third quarter of 2025. With strong results demonstrating production growth and an impressive cash position, the company declared a dividend of $0.01 per share for the upcoming fourth quarter. Financial Overview The company recorded...

Continue Reading
Examining Sustainability in Grape Seed Extracts Production

Updated Category News Views 172

PLT Health Solutions Unveils Sustainability Report for MegaNatural® Grape Seed Extracts PLT Health Solutions, Inc. has proudly released a comprehensive white paper that delves into the sustainability practices involved in the production of its MegaNatural® grape seed extracts. This insightful document showcases the efforts of California Natural Color, a division of...

Continue Reading
Market Stability Returns as VIX Experiences Significant Drop

Updated Category News Views 126

Understanding the Recent Decline in the VIX The CBOE Volatility Index, commonly known as the VIX, saw a notable decrease of 5%, nearing four-week lows. This decline signifies a shift in market sentiment, reflecting greater stability in investor outlook. The Impact of Political Changes on Volatility With the inauguration of a new U.S. President, the market has reacted...

Continue Reading
AlphaTON Capital Corp. Advances in Cancer Treatment Tokenization

Updated Category News Views 205

AlphaTON Capital Corp. Shares See Significant Gains AlphaTON Capital Corp. (NASDAQ: ATON) has recently garnered attention as its shares experience a notable surge in trading activity. This increase follows the company’s announcement of a non-binding letter of intent to assess the tokenization of single-indication economics for their promising cancer treatment, TT-4,...

Continue Reading